Overview

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Phase:
Phase 2
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Maleic acid
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol